Literature DB >> 15845900

Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells.

Susan K Nilsson1, Hayley M Johnston, Genevieve A Whitty, Brenda Williams, Ryan J Webb, David T Denhardt, Ivan Bertoncello, Linda J Bendall, Paul J Simmons, David N Haylock.   

Abstract

Although recent data suggests that osteoblasts play a key role within the hematopoietic stem cell (HSC) niche, the mechanisms underpinning this remain to be fully defined. The studies described herein examine the role in hematopoiesis of Osteopontin (Opn), a multidomain, phosphorylated glycoprotein, synthesized by osteoblasts, with well-described roles in cell adhesion, inflammatory responses, angiogenesis, and tumor metastasis. We demonstrate a previously unrecognized critical role for Opn in regulation of the physical location and proliferation of HSCs. Within marrow, Opn expression is restricted to the endosteal bone surface and contributes to HSC transmarrow migration toward the endosteal region, as demonstrated by the markedly aberrant distribution of HSCs in Opn-/- mice after transplantation. Primitive hematopoietic cells demonstrate specific adhesion to Opn in vitro via beta1 integrin. Furthermore, exogenous Opn potently suppresses the proliferation of primitive HPCs in vitro, the physiologic relevance of which is demonstrated by the markedly enhanced cycling of HSC in Opn-/- mice. These data therefore provide strong evidence that Opn is an important component of the HSC niche which participates in HSC location and as a physiologic-negative regulator of HSC proliferation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15845900     DOI: 10.1182/blood-2004-11-4422

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  262 in total

1.  The haematopoietic stem cell niche at a glance.

Authors:  Cristina Lo Celso; David T Scadden
Journal:  J Cell Sci       Date:  2011-11-01       Impact factor: 5.285

2.  Rac signaling in osteoblastic cells is required for normal bone development but is dispensable for hematopoietic development.

Authors:  Steven W Lane; Serena De Vita; Kylie A Alexander; Ruchan Karaman; Michael D Milsom; Adrienne M Dorrance; Amy Purdon; Leeann Louis; Mary L Bouxsein; David A Williams
Journal:  Blood       Date:  2011-11-28       Impact factor: 22.113

Review 3.  Stem cell interactions in a bone marrow niche.

Authors:  Joan Isern; Simón Méndez-Ferrer
Journal:  Curr Osteoporos Rep       Date:  2011-12       Impact factor: 5.096

4.  [Mesenchymal stem cells for bone tissue engineering].

Authors:  R K Schneider; S Neuss; R Knüchel; A Perez-Bouza
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

Review 5.  Molecular signaling of the epithelial to mesenchymal transition in generating and maintaining cancer stem cells.

Authors:  Gaoliang Ouyang; Zhe Wang; Xiaoguang Fang; Jia Liu; Chaoyong James Yang
Journal:  Cell Mol Life Sci       Date:  2010-03-18       Impact factor: 9.261

6.  An in vivo model to study and manipulate the hematopoietic stem cell niche.

Authors:  Junhui Song; Mark J Kiel; Zhou Wang; Jingcheng Wang; Russell S Taichman; Sean J Morrison; Paul H Krebsbach
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

Review 7.  Coexistence of quiescent and active adult stem cells in mammals.

Authors:  Linheng Li; Hans Clevers
Journal:  Science       Date:  2010-01-29       Impact factor: 47.728

8.  Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia.

Authors:  Benjamin J Frisch; John M Ashton; Lianping Xing; Michael W Becker; Craig T Jordan; Laura M Calvi
Journal:  Blood       Date:  2011-09-28       Impact factor: 22.113

Review 9.  Getting blood from bone: an emerging understanding of the role that osteoblasts play in regulating hematopoietic stem cells within their niche.

Authors:  Yusuke Shiozawa; Russell S Taichman
Journal:  Exp Hematol       Date:  2012-05-26       Impact factor: 3.084

10.  Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation.

Authors:  Christina Hart; Sabine Klatt; Johann Barop; Gunnar Müller; Roland Schelker; Ernst Holler; Elisabeth Huber; Wolfgang Herr; Jochen Grassinger
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.